New MS drug shows promise in chinese trial
NCT ID NCT05199571
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and monitor for side effects. Participants received the drug for 12 months, and researchers tracked relapse rates and MRI brain scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Lanzhou, Gansu, 730030, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510630, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
Harbin, Heilongjiang, 150001, China
-
Novartis Investigative Site
Wuhan, Hubei, 430030, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Taiyuan, Shanxi, 030001, China
-
Novartis Investigative Site
Ürümqi, Xinjiang, 830054, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Beijing, 065001, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Guangzhou, 510260, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shenzhen, 518036, China
-
Novartis Investigative Site
Tianjin, 300052, China